“NorthStar has quickly achieved several key milestones in advancing our strategically planned RadioGenix System roll-out,” said George P. Messina, Chairman and CEO of NorthStar. “First, the FDA approval of our Beloit manufacturing facility enables us to scale up production and expand capacity to meet anticipated customer demand. The approval came well in advance of the anticipated FDA action date. Second, we are also very pleased to announce that the commercial launch of the RadioGenix System has commenced, with the first contract signed and the first installation scheduled at a customer site. This important event marks another milestone in NorthStar’s commitment to provide the United States healthcare system with a reliable, domestic non-uranium based Mo-99 supply for production of the important medical diagnostic imaging radioisotope, technetium-99m. We anticipate shipping additional RadioGenix Systems as potential customers receive licensing amendments for their sites, and look forward to sharing our progress.” Read the full story here.
- ‘Reverse pitch’ by healthcare providers part of March 18 Tech Summit at LambeauFebruary 14, 2019
- InsideWis: Company speed dates aimed at matching big, emerging businessesFebruary 14, 2019
- How ‘smart’ is your city? Learn more at March 7 Tech Council event in WauwatosaFebruary 14, 2019
- Guest column: Quality healthcare in Wisconsin can boost state’s ability to attract business, workersFebruary 11, 2019
- Guest column: If you think your email is secure, think again!February 8, 2019